Tiragolumab is a monoclonal antibody commercialized by F. Hoffmann-La Roche, with a leading Phase III program in Esophageal Squamous Cell Carcinoma (ESCC). According to Globaldata, it is involved in 49 clinical trials, of which 6 were completed, 38 are ongoing, 1 is planned, and 4 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Tiragolumab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Tiragolumab is expected to reach an annual total of $358 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Tiragolumab Overview

Tiragolumab (RG-6058, MTIG-7192A, anti-TIGIT) is under development for the treatment of advanced or metastatic hepatocellular carcinoma (HCC), melanoma, bladder cancer, renal cell carcinoma,  advanced rectal cancer, advanced or metastatic solid tumors, head and neck squamous cell carcinoma (SCCHN) involving the oropharynx, oral cavity, larynx, or hypopharyngeal cancers, metastatic esophageal squamous cell carcinoma,  gastroesophageal junction carcinomas, triple negative breast cancer, B-Cell Non-Hodgkin Lymphoma, locally advanced, recurrent, or metastatic incurable tumors, adenocarcinoma of the cervix, small-cell lung cancer, brain metastases, non-squamous NSCLC, HER2 negative breast cancer and non-small cell lung cancer. The drug candidate is administered as an intravenous (IV) infusion. It acts by targeting TIGIT protein.

It was also under development for the treatment of relapsed/refractory multiple myeloma, gastric cancer or adenocarcinoma of gastroesophageal junction, relapsed/refractory B-cell non-Hodgkin lymphoma

F. Hoffmann-La Roche Overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

For a complete picture of Tiragolumab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.